Publications by authors named "Preeti Narayan"

Claim this Profile
U
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
Jennifer J Gao, Tatiana M Prowell, Haley Gittleman, Joyce Cheng, Mallorie Fiero, Preeti Narayan

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, Vishal Bhatnagar

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Shaily Arora, Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L Suzman

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Shaily Arora, Preeti Narayan, Christy L Osgood, Suparna Wedam, Tatiana M Prowell

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Preeti Narayan, Christy L Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K Ricks

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Preeti Narayan, Tatiana M Prowell, Jennifer J Gao, Laura L Fernandes, Emily Li

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan

Oncologist· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the Science and Future Directions for Liquid Biopsies in Drug Development.
Preeti Narayan, Soma Ghosh, Reena Philip, J Carl Barrett, Robert T McCormack

Oncologist· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Preeti Narayan, Sakar Wahby, Jennifer J Gao, Laleh Amiri-Kordestani, Amna Ibrahim

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients.
Rebecca S Twersky, Vasudha Goel, Preeti Narayan, Jeremy Weedon

Anesth Analg· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary myeloid sarcoma masquerading as an obstructing duodenal carcinoma.
Preeti Narayan, Vijayashree Murthy, Mu Su, Rosemonde Woel, I Robert Grossman

Case Rep Hematol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting edge: inhibition of T cell activation by TIM-2.
Jared E Knickelbein, Anjali J de Souza, Richard Tosti, Preeti Narayan, Lawrence P Kane

J Immunol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.
Preeti Narayan, Brittany Holt, Richard Tosti, Lawrence P Kane

Mol Cell Biol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis